Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical TrialAccesswire • 03/01/24
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesAccesswire • 02/16/24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesAccesswire • 02/15/24
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamGlobeNewsWire • 01/11/24
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformGlobeNewsWire • 01/09/24
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug SemaglutideAccesswire • 01/04/24
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot StudyAccesswire • 11/28/23
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot StudyAccesswire • 11/27/23
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsGlobeNewsWire • 10/31/23
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynAccesswire • 10/13/23
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBDAccesswire • 09/21/23
Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDAccesswire • 08/02/23
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyAccesswire • 07/28/23
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch ProductsAccesswire • 07/19/23
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular ScienceAccesswire • 06/22/23